Corpus ID: 41193840

Legal and ethical issues associated with patient recruitment in clinical trials: the case of competitive enrolment.

@article{Caulfield2005LegalAE,
  title={Legal and ethical issues associated with patient recruitment in clinical trials: the case of competitive enrolment.},
  author={Timothy Caulfield},
  journal={Health law review},
  year={2005},
  volume={13 2-3},
  pages={
          58-61
        }
}
Introduction The demand for patients for clinical trials continues to increase. There are more clinical trials being done (often involving patients with similar conditions), government regulators require an increasing amount of data for the drug approval process, and some within industry have speculated that patients are becoming less willing to participate. These pressures have led to the development of a variety strategies to make the recruitment of patients more efficient and effective, such… Expand

Topics from this paper

How Are the Interests of Incapacitated Research Participants Protected through Legislation? An Italian Study on Legal Agency for Dementia Patients
TLDR
The timing for appointment of a legal proxy in Italy is evaluated and predictive variables of appointment are identified, taking as examples other EU countries' systems. Expand
Frontiers: Integration of a Research Participant Registry with Medical Clinic Registration and Electronic Health Records
TLDR
The experience in establishing the Frontiers Research Participant Registry is reported and the unique combination of features that diffrentiate it from other registries are highlighted, which have yielded a highly successful program with a growing database of over 31,000 individuals who have agreed to be contacted for research recruitment. Expand
Disease modifying treatment trials in Parkinson’s disease: how to balance expectations and interests of patients, physicians and industry partners?
TLDR
It is concluded that the current competitive race for enrollment in clinical studies in PD is challenging the primary goal to ensure patients’ benefit and formulate requests to the industrial partners to encounter these concerns. Expand
Research Ethics Governance and Political Science in Canada
  • T. Porter
  • Political Science
  • PS: Political Science & Politics
  • 2008
The governance of research ethics in Canada, including its research ethics boards (REBs), which correspond to the institutional review boards in the U.S., often is portrayed as an exemplary model ofExpand
Better Regulation of Industry-Sponsored Clinical Trials is Long Overdue
  • M. Wynia, David K. Boren
  • Medicine
  • The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics
  • 2009
TLDR
All financial support for phase III clinical trials should pass through a public-private partnership organization--perhaps tied to a broader clinical effectiveness research enterprise--which would be charged with designing, funding, and monitoring late-stage human clinical trials of new pharmaceutical products. Expand
Reconceptualising the Doctor–Patient Relationship: Recognising the Role of Trust in Contemporary Health Care
TLDR
This article presents a rationale and framework for an alternative model—a “Trust Model”—for implementation into law to more accurately reflect the contemporary therapeutic dynamic. Expand
Assessing Clinical Trial Informed Consent Comprehension in Non-Cognitively-Impaired Adults: A Systematic Review of Instruments
TLDR
These are the first standardized instruments developed to assess comprehension in non-cognitively-impaired adults, and each instrument had its own set of limitations such as the lack of generalizability and the absence of details pertaining to how test results should be used to guide clinical decision-making. Expand
Accrual monitoring in cardiovascular trials
Objective To provide brief guidance on how to design accrual monitoring activities in a clinical trial protocol. Setting Two completed clinical trials that did not achieve the planned sample size,Expand
Epidemiology of clinical trials of medicines in respiratory diseases in Europe and Italy.
TLDR
Europe has a greater potential for clinical research on drugs for respiratory diseases, particularly in countries with less activity, such as Spain, France and Italy, that should identify and implement actions to increase attractiveness for clinical trials of drugs. Expand
Experimental heterogeneity and standardisation: Stem cell products and the clinical trial process
This article examines developments in the field of regenerative medicine with respect to two quite distinct models of therapeutic development, a medical innovation model and a ‘cells-as-drugs’ model.Expand
...
1
2
...

References

SHOWING 1-6 OF 6 REFERENCES
The report of the committee of inquiry on the case involving Dr. Nancy Olivieri: a fiduciary law perspective.
Fiduciary law is highly instructive about the limits of what may be agreed to by physician-researchers and sponsor drug companies when their agreements implicate the interests of patients whoExpand
Dealing with conflicts of interest in biomedical research: IRB oversight as the next best solution to the abolitionist approach.
  • J. A. Goldner
  • Medicine, Political Science
  • The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics
  • 2000
TLDR
Institutional review board oversight at the level of the relationship between researcher and individual subjects as the next best solution to conflicts of interest is proposed. Expand
Enrolling patients into clinical trials faster using RealTime Recuiting
TLDR
This work describes a clinical trial needing a real-time method of recruiting patients in an unbiased manner, quickly enough that study tests can be obtained before patients leave or samples discarded. Expand
Rev Up Patient Recruitment
  • 2002
Wynrib [1992] 2 S.C.R
  • McInerney v. MacDonald [1992],
  • 2002